

FOI 1797

20.07.2023

**FREEDOM OF INFORMATION ACT 2000 – INFORMATION REQUEST**

---

**Q1. How many patients were treated in the past 3 months for gastric and gastro-oesophageal junction cancer (any stage) with:**

- **CAPOX (Capecitabine with Oxaliplatin)**
- **FOLFOX (Folinic acid, Fluorouracil and Oxaliplatin)**
- **Lonsurf (Trifluridine - tipiracil)**
- **Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)**
- **Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)**
- **Any other systemic anti-cancer therapy**
- **Palliative care only**

Information not held.

**Q2. How many patients were treated in the past 3 months for Oesophageal cancer (any stage) with:**

- **Nivolumab monotherapy or combination with Ipilimumab**
- **Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)**
- **Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)**
- **Platinum and Fluoropyrimidine based combination treatments (Cisplatin or Oxaliplatin with 5-Fluorouracil or Capecitabine)**
- **Any other systemic anti-cancer therapy**
- **Palliative care only**

Information not held.

**Q3. How many patients were treated in the past 3 months for advanced/metastatic resected oesophageal cancer ONLY with:**

- Nivolumab monotherapy or combination with Ipilimumab
- Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)
- Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)
- Platinum and Fluoropyrimidine based combination treatments (Cisplatin or Oxaliplatin with 5-Fluorouracil or Capecitabine)
- Any other systemic anti-cancer therapy
- Palliative care only

Information not held.

**Q4. In the past 3 months, how many patients have been initiated\* on the following agents for treatment for gastric, gastro-oesophageal junction or Oesophageal cancer:**

- Nivolumab monotherapy or in combination with Ipilimumab
- Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)
- Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)

**\*Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.**

Information not held.

**Q5. Does your trust participate in any clinical trials for gastric cancer? If so, please provide the name of each trial and the number of patients taking part.**

Information not held.

**Q6. Does your trust participate in any clinical trials for oesophageal cancer? If so, please provide the name of each trial and the number of patients taking part.**

Information not held.

These cancers are treated at the Belfast Health & Social Care Trust.

You may wish to contact them by email to [publicliaison@belfasttrust.hscni.net](mailto:publicliaison@belfasttrust.hscni.net)

Email: [Foi.Team@Southerntrust.hscni.net](mailto:Foi.Team@Southerntrust.hscni.net)